CD19 expression + Chr t(8;21)

Lymphodepletion included fludarabine and cyclophosphamide...All pts developed CRS (grade 1-3) and were treated with supported treatment and 3/6 pts received i.v tocilizumab and/or dexamethasone...Six months post-transplant the pt relapsed again, responded to azacitidine/venetoclax combination, and, was in CR for 11 months but then relapsed and died...We presented 6 pts with R/PR t (8; 21) AML with aberrant CD19 expression after multiple lines of therapies (4 post allo-SCT), treated by point of care CD19 CAR T-cells with 4 pts achieving CR. CD-19 CAR T cells administration for AML is feasible and safe. However, the response is short and should be followed by a second transplant or alternative anti leukemic therapies.